Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04762225 · ClinicalTrials.gov registry record · Phase 1
RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma
A Phase 1 study, sponsored by Repertoire Immune Medicines.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04762225: Clinical Trial Phase 1 study, sponsored by Repertoire Immune Medicines.
NCT04762225 is a Phase 1 study that was terminated before completion, run by Repertoire Immune Medicines. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04762225, a Phase 1 study, was terminated before completion, sponsored by Repertoire Immune Medicines.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
Primary Outcome
Safety of RPTR-168:1 as a monotherapy in patients with melanoma
Interventions
- BIOLOGICAL RPTR-168
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 1 |
Why NCT04762225 stopped before completion
NCT04762225 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which RPTR-168 is the first listed.
NCT04762225 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04762225 about?
NCT04762225 is a clinical study titled "RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma". The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.
What is the current status of trial NCT04762225?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-05-10. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT04762225?
The interventions under investigation include: RPTR-168 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04762225?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04762225's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI